Our team of life science professionals has extensive experience in discovering and developing treatments for cardiometabolic diseases, including obesity and diabetes. Our mission is to target multiple disease-causing mechanisms through innovative …

2024年5月22日 · At SixPeaks Bio we believe that protection of lean tissue mass will be a core component for future healthy weight management solutions. We are targeting preservation and potentially an expansion of skeletal muscle mass as a future therapeutic companion to GLP1 RAs.

Passionate leader and pharmaceutical/biotechnology quality executive as analytical chemist with > 20 years’ experience in pharmaceutical industry. SixPeaks Bio | 1,226 followers on LinkedIn....

2024年5月22日 · A new obesity drug developer from investment firm Versant Ventures is starting up with a deal to possibly sell itself to AstraZeneca. The startup, called SixPeaks Bio, launched Wednesday with $30 million in Series A funding led by Versant and involving AstraZeneca.

2024年5月22日 · SixPeaks was founded in 2022 at Versant’s Ridgeline Discovery Engine in the Basel Technology Park with the goal of developing improved therapies for healthy weight loss. The SixPeaks team leveraged...

2024年5月22日 · BASEL, Switzerland-- (BUSINESS WIRE)--SixPeaks Bio AG today emerged from stealth mode with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors.

2024年5月22日 · SixPeaks is the latest biotech to jump on the bandwagon. Preclinical data from mice has shown that the company’s lead compound had “best-in-class” efficacy while …

2024年5月25日 · SixPeaks成立于2022年，目标是开发更加健康的减肥疗法，其管线包括一款潜在best-in-class的靶向activin IIA/B receptor的双特异性抗体。 这款创新疗法有望在减肥的同时，保护人类骨骼肌质量。 GLP-1药物如今风靡全球，但患者在减少体脂时同时也会减少肌肉质量（肌肉流失），这可能限制此类药物的长期使用。 临床前研究表明，在瘦鼠和肥胖小鼠模型中，SixPeaks的先导分子无论是单独使用还是与GLP-1R激动剂联合使用，都显示出潜在best-in-class的肌肉 …

Find company research, competitor information, contact details & financial data for SixPeaks Bio AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.

Developer of weight-loss therapies intended for patients suffering from obesity. The company's platform provides dual-specific antibodies targeting activin type IIA and B receptors for robust preservation of skeletal muscle mass in humans, enabling patients to lose muscle mass in addition to reductions in body fat. LOHAS & Wellness, Life Sciences.